Last reviewed · How we verify

NCT06756906

Comparison of High Flow Nasal Oxygen and Nasal Cannula in Burn Patients Under Sedation

Recruiting now Last updated 3 January 2025
What this trial tests

trial in Burn Injury in 70 participants. Currently enrolling.

Timeline
15 July 2024
Primary endpoint
27 January 2025
10 February 2025

Quick facts

Lead sponsorAnkara City Hospital Bilkent
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment70
Start date15 July 2024
Primary completion27 January 2025
Estimated completion10 February 2025
Sites1 location across Turkey (Türkiye)

Conditions studied

Sponsor

Ankara City Hospital Bilkent

Who can join

18 and older, any sex, with Burn Injury or Hypoxia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Burn-related pain is severe and often difficult to manage. Burn patients often require high doses of opioids and anxiolytics. Anesthetic agents used during sedation such as benzodiazepines, propofol and opioids can cause respiratory depression, predisposing patients to hypoventilation and hypoxemia due to airway obstruction. Oxygen is administered to patients with a standard nasal cannula during sedation. High Flow Nasal Oxygen (HFNO) helps to improve the oxygenation of patients with respiratory distress by delivering high flow humidified oxygen through the nasal cannula at a high rate of up to 40-70 liters per minute. The aim of this study was to compare the effects of HFNO and nasal oxygen therapy in preventing hypoxemia in deeply sedated burn patients.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Burn Injury

Currently open trials in the same condition.

Other Ankara City Hospital Bilkent trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06756906.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing